KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Assets: 2013-2024

Historic Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $162.9 million.

  • Xenon Pharmaceuticals' Non-Current Assets fell 27.55% to $127.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.7 million, marking a year-over-year decrease of 27.55%. This contributed to the annual value of $162.9 million for FY2024, which is 49.08% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Non-Current Assets of $162.9 million as of FY2024, which was down 49.08% from $319.8 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Non-Current Assets peaked at $319.8 million during FY2023, and registered a low of $7.4 million during FY2020.
  • In the last 3 years, Xenon Pharmaceuticals' Non-Current Assets had a median value of $162.9 million in 2024 and averaged $212.2 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Non-Current Assets soared by 1,084.63% in 2022 and then slumped by 49.08% in 2024.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Non-Current Assets stood at $7.4 million in 2020, then spiked by 75.43% to $13.0 million in 2021, then surged by 1,084.63% to $153.8 million in 2022, then skyrocketed by 107.89% to $319.8 million in 2023, then plummeted by 49.08% to $162.9 million in 2024.